联合检测MMP2和MMP9在冠状动脉粥样硬化性心脏病患者中的临床意义-东南大学学报医学版

联合检测MMP2和MMP9在冠状动脉粥样硬化性心脏病患者中的临床意义

单位：1. 华中科技大学同济医学院附属武汉中心医院, 检验科, 湖北武汉 430014;
2. 华中科技大学同济医学院附属武汉中心医院, 影像科, 湖北武汉 430014

分类号：R541.4

出版年·卷·期（页码）：2019·38·第一期（51-56）

摘要：

目的：观察不同类型冠心病患者血清基质金属蛋白酶-2（MMP2）、基质金属蛋白酶-9（MMP9）水平的变化，探讨MMP2和MMP9在预测不同类型冠心病中的临床意义。方法：收集我院冠心病患者标本486例，其中稳定性冠心病患者162例，心肌梗死患者173例，不稳定型心绞痛患者151例，对照组为来我院体检的健康者529例，用酶联免疫吸附试验（ELISA）法检测其血清中MMP2和MMP9水平，绘制ROC曲线，比较MMP2及MMP9的诊断价值。结果：冠心病组MMP2和MMP9水平明显高于对照组（P<0.05），在冠心病组中不稳定心绞痛组的MMP2和MMP9明显高于稳定性冠心病组及心肌梗死组，在急性冠脉综合征患者中联合检测MMP2和MMP9的ROC曲线下面积为0.727。结论：患者血清MMP2和MMP9水平显著增高提示了粥样斑块的不稳定性，联合检测MMP2和MMP9在急性冠脉综合征中具有很高的诊断价值。

Objective:To investigate the changes in serum matrix metalloproteinases-2 and-9(MMP2 and MMP9)levels in patients with different types of coronary heart disease(CHD) and assess the value of MMP2/MMP9 detection in predicting CHD.Methods:According to the findings of coronary angiography and the clinical manifestations 486 patients were divided in CHD group including 162 patients with stable coronary heart disease and 173 patients with myocardial infarction and 151 patients with unstable angina pectoris.529 individuals with normal coronary artery served as the control group.Plasma levels of MMP2 and MMP9 were determined in these subjects using enzyme-linked immunosorbent assay(ELISA) and ROC curve.Results:The coronary heart disease(CHD) groups showed significantly higher MMP2 and MMP9 levels than the control groups(P<0.05),compared with the AMI and the stable angina pectoris patients groups,the unstable angina pectoris patients showed obvious increase in serum MMP2 and MMP9 levels.The AUC of combined detection of MMP2 and MMP9 was 0.727.Conclusions:Serum MMP2 and MMP9 levels were significantly increased in patients with atheromatous plaque instability, combined detection of MMP2 and MMP9 in acute coronary syndrome has a high diagnostic value.

参考文献：

[1] MANGINAS A,BEI E,CHAIDAROGLOU A,et al.Peripheral levels of matrix metalloproteinase-9,in-terleukin-6,and C-reactive protein are elevated in patients with acute coronary syndromes:correlations with serum troponin I[J].Clin Cardiol,2012,28(4):182-186.
[2] NEWBY A C.Matrix metalloproteinase inhibition therapy for vascular diseases[J].Vascul Pharmacol,2012,56(5-6):231-44.
[3] ZALDIVIA M T K,MCFADYEN J D,LIM B,et al.Platelet-derived microvesicles in cardiovascular diseases[J].Front Cardiovasc Med.2017,4:74.
[4] WEBER C,NOELS H.Atherosclerosis:Current pathogenesis and therapeutic options[J].Nat Med,2011,17:1410-1422.
[5] SIERRA S,LUQUIN N,NAVARRO-OTANO J.The endocannabinoid system in cardiovascular function:novel insights and clinical implications[J].Clin Auton Res,2017,(17):488-492.
[6] AMIRALA B N,HUTCHESON J D,ELENA A.Extracellular vesicles as mediators of cardiovascular calcification[J].Front Cardiovasc Med,2017,4:78.
[7] ROSSANO R,LAOCCA M,RIVIELLO L,et al.Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants[J].Cell Mol Med,2014,18(2):242-252.
[8] ORLANDI A.The contribution of resident vascular stem cells to arterial pathology[J].Int J Stem Cells,2015,8(1):9-17.
[9] SANDERSON R D,BANDARI S K,VLODAVSKY I.Proteases and glycosidases on the surface of exosomes:Newly discovered mechanisms for extracellular remodeling[J].Matrix Biol,2017,(17):30311-30316.
[10] MICKLEBURG I,BURTLE B,NURY D,et al.Isolation and identification of a protein binding to the localization element of metallothionein-1 mRNA[J].Biochem Soc Trans,2014,32(5):705-706.
[11] JONES GT,TROMP G,KUIVANIEMI H,et al.Meta-analysis of genome-wide association studies for abdominal aortic aneurysm identifies four new disease-specific risk loci[J].Circ Res,2017,120(2):341-353.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录